Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


August 29, 2015 3:00 PM ET

Healthcare Equipment and Supplies

Company Overview of EKOS Corporation

Company Overview

EKOS Corporation engages in the development and clinical application of ultrasound infusion technologies for the treatment of vascular thrombosis. The company develops EkoSonic and MicroSonic SV endovascular devices for the controlled and selective infusion of physician-specified fluids, including thrombolytics into the peripheral vasculature. Its products are used by interventional radiologists, cardiologists, and cardiothoracic and vascular surgeons at various institutions around the world. The company was founded in 1995 and is based in Bothell, Washington. As of July 5, 2013, EKOS Corporation operates as a subsidiary of BTG International Inc.

11911 North Creek Parkway South

Bothell, WA 98011

United States

Founded in 1995

Phone:

425-415-3100

Fax:

425-415-3102

Key Executives for EKOS Corporation

Controller
Vice President and General Manager
Vice President of Regulatory & Clinical Affairs
Vice President of Systems Integration
Vice President of Operations
Compensation as of Fiscal Year 2015.

EKOS Corporation Key Developments

EKOS Corporation Announces the Publication of Results of the SEATTLE II Trial in the JACC: Cardiovascular Interventions

EKOS Corporation announced the publication of results of the SEATTLE II trial in the JACC: Cardiovascular Interventions. The study concluded that treatment with ultrasound-facilitated catheter-directed low-dose thrombolysis for acute pulmonary embolism (PE) improves right heart function, reduces blood clot size, and decreases pulmonary hypertension in patients with intermediate to high risk PE. Importantly, no patient experienced intracranial hemorrhage, a serious adverse experience related to full-dose thrombolysis treatment. The SEATTLE II study was a prospective, single-arm, multi-center trial designed to evaluate the safety and effectiveness of ultrasound-facilitated catheter-directed low-dose thrombolysis, using the EKOS EkoSonic® Endovascular System. One-hundred fifty (150) patients diagnosed as acute massive (N=31) or submassive (N=119) PE were enrolled. Patients received low dose (24 mg) of tPA (thrombolytic) for 24 hours with a unilateral catheter or for 12 hours with bilateral catheters. The size of the right heart measured as RV/LV ratio significantly decreased from 1.55 to 1.13 (p<0.0001) by 48 hours after start of treatment. For patients with severe PE, the mortality rate is nearly one third1. In the SEATTLE II study 31 patients presented to the emergency room with massive PE, syncope and hypotension. All 31 survived the 30-day follow up period. Of 150 patients in the study, one death was directly attributed to PE. There were no intracranial hemorrhages and no fatal bleeding events. Major bleeds occurred in 15 patients and were comprised of one severe bleed and 16 moderate bleeds. Six of the major bleeds occurred in patients with co-morbidities known to be associated with an increased risk of bleeding during thrombolytic therapy.

EKOS Corporation Initiates a Pivotal New Study in Patients with Chronic Deep Vein Thrombosis and Post-Thrombotic Syndrome

EKOS Corporation announced the start of patient enrollment for the ACCelerated ThrombolySiS for Post-Thrombotic Syndrome using the EKOS(R) System (ACCESS PTS) Study. The ACCESS PTS study is a prospective, single-arm, multi-center trial, designed to evaluate the safety and efficacy of ultrasound accelerated thrombolysis using the EkoSonic(R) Endovascular System with standard infusion of a thrombolytic drug for PTS and chronic venous occlusions. The study will enroll up to 200 subjects over a period of 12 months at approximately 30 study sites across the United States. Subjects will receive clinical follow-up for 12 months. Clinical effectiveness will be evaluated using the Villalta score (measurement of the severity of PTS) at baseline compared to 30 days post-EkoSonic(R) treatment. Success will be defined by 50% or more of the subjects achieving at least a 4 point reduction in the Villalta score, which represents a significant improvement in the symptoms of PTS. Potential study subjects will be between 18 and 75 years of age with lower extremity DVT who have: Been objectively diagnosed via imaging as having persistent DVT for at least 6 months. A Villalta score >=8. Failed 3 months of conservative treatment including compression stockings and anticoagulation drugs.

EkoSonic Endovascular System Receives FDA Clearance for the Treatment of Pulmonary Embolism in the USA

EKOS Corporation announced that the U.S. Food and Drug Administration has cleared the EkoSonic Endovascular System for the ultrasound facilitated, controlled and selective infusion of physician-specified fluids, including thrombolytics, into the vasculature for the treatment of pulmonary embolism. The EKOS ultrasonic devices are designed to gently accelerate the penetration of thrombolytic agents into thrombus, providing high levels of lysis. EKOS is the only minimally invasive endovascular therapy on the market that has been FDA cleared for the treatment of PE.

Similar Private Companies By Industry

Company Name Region
COR Innovations, Inc United States
Erchonia Corporation United States
Prisma Medical Technologies LLC United States
For Eyes Optical Company, Inc. United States
Kardiothor, Inc. United States

Recent Private Companies Transactions

Type
Date
Target
No transactions available in the past 12 months.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
NYC2012, Inc. United States
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact EKOS Corporation, please visit www.ekoscorp.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.